Introduction
The infusion of ex vivo expanded TIL has resulted in objective clinical responses in approximately 50 % of patients with metastatic melanoma [1] which could be further increased by myeloablative preparative regimens [2] . The need for TIL as a T-cell source has limited the extension of this approach to cancers such as breast, lung, and colorectal cancer where metastatic lesions are visceral or boney and harvesting TIL would be difficult. Peripheral blood has not been commonly exploited as a source of T-cells for adoptive T-cell therapy as tumor-specific T-cells are found in higher numbers in the cancer as TIL compared to the peripheral blood and more readily expanded [3] . Moreover, the culture conditions needed to expand rare T-cells from the peripheral blood have not been well developed, especially for antigen-specific CD4
+ T-cells. Studies by our group have shown that patients with metastatic breast cancer can be immunized against HER2 resulting in significant increases in HER2-specific peripheral blood T-cells as well as a broadening of the immune response to additional antigens expressed by the tumor, i.e., epitope spreading [4] . We developed T-cell culture methods that would enrich for and preserve the epitope spreading elicited with vaccination [5, 6] . Data presented here demonstrate the feasibility of expanding HER2-specific T-cells from the peripheral blood of previously vaccinated patients and evaluate the safety and immunogenicity of the approach.
Methods

Patient population
After informed consent, patients were enrolled into the IRB approved trial from 2003 . Major enrollment criteria were as follows: (1) treatment refractory HER2 + cancer, (2) lesions (>1 cm) which could be quantitatively assessed by imaging, (3) previously received HER2 vaccinations, and (4) not received standard therapies for at least 1 month prior to the first T-cell infusion.
Study design
The trial was a phase I, 2-arm study. For safety concerns, cells were administered as an intrapatient dose escalation with limits of 1.0 × 10 9 (dose 1), 1.0 × 10 10 (dose 2), and 1.0 × 10 11 (dose 3) total cells given after administration of a single dose of cyclophosphamide (600 mg/m 2 ) (Patients A-E) or denileukin diftitox (ONTAK) (18 mg/kg) (Patients F-H) 24 h prior to the first infusion. The ability to expand T-cells was defined as feasible if a minimum expansion (1-log less than the maximum dose) was achieved in the majority of expansions in 80 % of subjects enrolled. A specific dose was defined as safe if 4 of 5 patients in a study arm experienced no dose-limiting toxicity (DLT). Toxicity was evaluated according to CTEP CTCAE v3.0 criteria.
Secondary objectives included the extent HER2-specific T-cell immunity could be boosted with infusion and persist and clinical response as measured by the comparison of pre-and post-treatment imaging using RECIST criteria. Target lesions were defined as the largest measurable lesion prior to treatment, although measurements were made on all lesions during the course of the study. Immune parameters were assessed prior to infusion and at various time points after the active treatment period had ended. Concurrent use of bisphosphonates was allowed (Patients B, C, D, E, H).
Planned enrollment was 10 patients, 5 receiving conditioning with cyclophosphamide and 5 with ONTAK. After 3 patients were enrolled on the ONTAK arm of the study, the manufacturer of the drug discontinued production and, due to the inability to complete the study as designed, the trial was closed with 8 patients enrolled.
Expansion of T-cells PBMC were purified from leukaphereses using FicollHypaque density gradient centrifugation. After washing, PBMC were aliquoted and cryopreserved in plasmalyte-A (Baxter) with 10 % DMSO (Sigma-Aldrich) and 10 % human serum albumin (CSL Behring LLC) and stored in liquid nitrogen. At the time of clinical expansion, cells were cultured over a 24 days according to previously published methods [5, 6] . In brief, PBMC were stimulated with a peptide pool of three HER2 MHC class II epitopes (Genemed Synthesis Inc) to which the patient had generated the greatest magnitude cellular immune response after the vaccination (10 ug/ml each peptide) [7, 8] . IL-12 (10 ng/ml) and IL-2 (10 u/ml) were added to the cultures on days 4 and 8, and the cultures were subsequently expanded with CD3/ CD28 beads on day 12 in IL-2 for 12 days. HER2 reactive T-cells increased approximately tenfold during expansion [5] . Release criteria included sterility, >70 % CD3
+ T-cells, and >70 % viable (Suppl. Table 1 ). Cell products were administered at 10 ± 3 day intervals.
Elispot
A 3-day IFN-γ ELISPOT assay was used to determine the frequencies of HER2-specific T-cells in the products using published methods [5] . Antigens evaluated included nine HER2 MHC class II epitopes (10 ug/ml), HER2 intracellular domain (ICD); 1 ug/ml (SignalChem) and extracellular domain (ECD); 1ug/ml (Sino Biological) proteins. These peptides and proteins were either the immunizing antigens in the patients' vaccine or antigens to which they had developed intramolecular epitope spreading [7] . Three HER2-specific MHC class I epitopes, p369-377, p689-p697, and p971-979, were used to interrogate T-cells from 4 HLA-A2 + patients. Data are presented as the mean IFN-γ spots/million T-cells calculated from six-well replicates subtracted from no-antigen wells (Corrected (c) IFN-γ spots/10 6 ). The estimated total number of HER2-specific IFN-γ-secreting T-cells infused in each patient was calculated by: total number of cells infused x cIFN-γ HER2 spots per 10 6 /10 6 . A 10-day IFN-γ ELISPOT was used assess responses in PBMC before and after T-cell infusions using previously described methods [4] . Data are expressed as corrected spots/10 6 cells (cIFN-γ HER2 spots/10 6 ).
Flow cytometry
Antibodies used included CD8 FITC, CD4 PE-Cy7, CD3 PerCP/Cy5.5, CD279 (PD-1) APC (Biolegend). The levels of T-regulatory cells (Treg) in all specimens were assessed as we have published [5] . 
, CD11b
+ MDSC in the total PBMC population. The stained cells were acquired with FACS Canto flow cytometer (BD Bioscience) and analyzed using FlowJo software.
T-cell receptor (TCR) repertoire diversity analysis
CD4
+ and CD8 + T-cell subsets from cell products and PBMC obtained pre-and post-infusion were separated using magnetic microbeads coated with an anti-CD4 or CD8 antibody (Invitrogen). The purity of each T-cell subpopulation was >95 % as determined by flow cytometry. Total RNAs were isolated from the purified CD4
+ and CD8 + T-cell subsets using a total RNA isolation kit (Qiagen). TCR Vβ repertoire analysis was performed using SuperTCRExpress human CDR3 diversity determination kit (BioMed Immunotech) [9] .
Statistical analysis
Statistical analysis was performed using GraphPad Prism (GraphPad Software). The differences between two groups (pre-infusion vs. post-infusion; responding patients vs. non-responding patients) were analyzed using a two-tailed Student's t test. Strengths of the relationship between the changes of tumor size after T-cell therapy and other factors were analyzed by Pearson's product moment correlation. A p < 0.05 was considered statistically significant.
Results
Clinical expansion of HER2 vaccine-primed T-cells from the peripheral blood of advanced stage cancer patients is feasible
One HER2
+ ovarian cancer patient and 7 HER2 + breast cancer patients were enrolled (Table 1) . T-cells were expanded from mononuclear cells obtained by leukapheresis a median of 1.8 months prior to the first infusion. Four patients received all three planned T-cell infusions, and four patients received only two infusions due to the low number of cells collected at the time of initial leukapheresis. T-cell products met or exceeded minimal requirements for cell expansion in seven of eight patients (88 %). The mean (±SE) fold increase in the growth of cells from 2 or 3 expansions for each subject is shown in Fig. 1a . For the group as a whole, the median fold increase in growth of cells from the start to the end of the culture was 8.3, range 0.2-22.1 (Fig. 1a , Suppl. Table 1 ). Cell products from 1 patient could not be adequately expanded ex vivo. She received the two low yield products that were generated and returned to her primary care physician with no further scheduled imaging or laboratory evaluations. The median total number of T-cells infused for successful expansions was 10,127 × 10 6 , range 1,692-47,207 × 10 6 with a median (range) of CD3 + 99 % (74-100 %), CD4
+ 38 % (13-46 %), and CD8 + T-cells 58 % (49-80 %) (Suppl. Table 1 ).
We examined the frequency of several populations of IFN-γ producing HER2-specific T-cells within the infused product using material derived from the first or second expansion for the seven remaining patients. The mean cumulative number of IFN-γ secreting T-cells per million cells for each category of antigen analyzed, for each subject, is shown in Fig. 1b . For all products, the median (range) of HER2 epitope-specific T-cells, for peptides that were used to stimulate the cultures, was 206 × 10 6 (undetectable-1,492) T-cells. The median (range) of HER2 protein-specific T-cells, for both the HER2 ECD and ICD, was 211 × 10 6 (31-1,702 × 10 6 ) T-cells. The ability of the T-cells to respond to recombinant protein processed and presented by autologous APC is an in vitro indicator of potential in vivo activity. The median (range) of HER2 epitope-specific T-cells, for peptides which represented epitope spreading from the original vaccination, was 366 × 10 6 (85-2,240 × 10 6 ) T-cells. Vaccination with HER2 class II peptides, designed to stimulate CD4 + T-cell responses, has been shown to induce HER2-specific CD8 + T-cells [8] . Four of the patients were HLA-A2
+ which allowed assessment of the expansion of class I HER2-specific T-cells. Mean responses are shown in Fig. 1c . For HLA-A2 + patients, the median (range) of HER2 class I epitope reactive T-cells was 1,527 × 10 6 (80-7,428 × 10 6 ). Figure 1d depicts the estimated total number of HER2-specific T-cells, of any measured specificity, that were infused during the two or three infusions. For all products, a median (range) of 36 × 10 6 (1-265 × 10 6 ) HER2-specific T-cells was infused.
The majority of adverse events associated with the infusion of HER2 vaccine-primed autologous T-cells are grade 1 and 2
One hundred and forty-three adverse events (AE) were collected during the trial, and none were classified as DLTs (Table 2, Suppl. Table 2 ). Of all AE, 71 % were grade 1, 21 % grade 2 with 8 % grade 3 or 4. The most common and significant AE were those expected from treatment with cyclophosphamide, ONTAK, or related to disease progression (Table 2, Suppl. Table 2 ). Significant pulmonary toxicity has been reported with the infusion of HER2-specific chimeric antigen receptor modified T-cells [10] . Such toxicity was not observed on this study, 6 pulmonary associated AEs were reported, all grade 1.
Three patients had evidence of potential infusioninduced inflammation at the site of metastases. An ovarian cancer patient developed severe abdominal pain consistent with peritonitis 2 weeks after her third infusion. Imaging revealed increased ascites and edematous mesentery. The CA-125 had risen from 61 to 101 U/ ml. Evaluation revealed no infectious etiology and she returned to her primary physician where, in the absence of additional therapy, her symptoms resolved and the CA-125 declined to 69 U/ml over 1 month. The second patient, with extensive lymph node metastases, developed increased tenderness and swelling in a right supraclavicular lymph node beginning 7 days after her last infusion. Symptoms resolved without treatment over a period of 2 weeks. A final patient with disease progression after treatment, in a solitary liver metastasis, had evidence of a 30 % increase in tumor size at imaging 21 days after her last infusion. The true extent of progression was obscured by a concomitant marked increase in peritumoral edema.
T-cell expansion, persistence, and diversity in vivo after infusion of HER2 vaccine-primed autologous T-cells
We examined the magnitude of the IFN-γ response to the HER2 antigens used to stimulate the T-cell products in the peripheral blood of patients after infusion. There was significant increase in these T-cells in vivo, compared to levels Fig. 2a) . The IFN-γ T-cell responses for all HER2 antigens in each individual patient at time points ranging from 10 to 280 days after the first T-cell infusion are shown in Supplemental Fig. 1 (persistent lymphopenia precluded immune assessment at day 20 in all but two patients). T-cell responses to all HER2 antigens could be maintained at elevated levels compared to baseline, in the majority of patients (4/6, 66 %), over 70-280 days after the first infusion; post-infusion mean ± SE: 3,072 ± 882 × 10 6 versus pre-infusion 1,539 ± 565 × 10 6 PBMC (Suppl. Fig. 1) . In three patients, HER2-specific T-cells continued to augment in vivo >100 days from the first infusion (Suppl. Fig. 1 ).
Mean levels of FOXP3 + CD4 + are shown for each patient (Fig. 2b) . As a group, there was no significant difference between pre-infusion and post-infusion Treg levels (mean ± SEM: pre-infusion, 2.5 ± 0.4 % vs. post-infusion 3.5 ± 0.8 %), p = 0.282 (Suppl. Fig. 2A ). In general, levels of Treg in the product were not increased by the culture method (mean ± SEM: 1.6 ± 0.3) as compared to pre-infusion levels, p = 0.115. The number of Treg in the peripheral blood after infusions had been completed was not significantly different between cyclophosphamide and ONTAK preconditioned groups, p = 0.110. There was no significant difference in the level of MDSC between preand post-infusion PBMC in the group, p = 0.260 (Fig. 2c , example, Suppl. Fig. 2B) .
Broadening of the TCR repertoire and the development of multiple clonal species over a short period of time has been associated with epitope spreading in exacerbations of autoimmune disease [11] . As expected, the majority of Fig. 3 ). However, after infusion in some patients, multiple TCR clonal populations [12] developed in specific CD4 + and CD8
+ T-cell populations (Table 3 , Supplemental  Fig. 3 ). The median (range) number of clonal TCR identified in pre-infusion peripheral blood was 4 (1-14), while post-infusion the median number was 10 (3-17).
Immune parameters associated with clinical response
All patients had sites of soft tissue metastases. The most common sites of metastatic lesions were liver (75 %), lymph node (50 %), and bone (50 %). Seventy-five percent of patients had more than one site of metastasis (median 2, range 1-4). All patients had measurable disease documented by standard imaging techniques a median of 5 days prior to the first T-cell infusion. Imaging performed a median of 21 days after the last infusion was used to calculate response of target lesions. The overall response rate in the 7 evaluable patients was 43 % (0 CR and 3 PR (8, 4, and 3 months duration)) with reductions in target lesions ranging from 57 to 77 % (Fig. 3a) . In all 3 responders, all lesions responded, i.e., no mixed responses. In Patient C, however, a new bone lesion developed after the first infusion. The remainder of the patients demonstrated progression in target lesions, ranging 25-50 %.
We performed univariate analyses evaluating quantitative immune parameters between responding and nonresponding patients and assessed significant associations (Suppl. Table 3 ). The % of Treg in the peripheral blood of the patients prior to T-cell infusion was associated with response, with higher levels of Treg found in those patients who progressed (p < 0.001, R 2 = −0.989) (Fig. 3b) . Treg levels in the infused product or found in the peripheral blood after infusion gave no such association (Suppl. Table 3 ). Two immune parameters assessed, in vivo, after T-cell infusions had been completed were also correlated with response. The greater the number of T-cells specific for the epitopes used to stimulate the T-cell cultures in the peripheral blood, the more likely a clinical response was observed (p = 0.030, R 2 = 0.642) (Fig. 3c) . The development of new TCRVβ species demonstrating clonality was also associated with those patients who demonstrated tumor regression (p < 0.001, R 2 = 0.967) (Fig. 3d) .
Discussion
The infusion of tumor-competent T-cells allows T-cells to be activated outside the immune suppressive environment of an existing cancer and has the potential of increasing the number of T-cells over what can be achieved with vaccination alone. Data presented here demonstrates expansion of HER2 vaccine-primed autologous T-cells is feasible, and infusions are associated with minimal toxicity that HER2-specific T-cells can be augmented in vivo by adoptive transfer and may persist at elevated levels for months in some patients. We additionally explored immune biomarkers that may be associated with clinical response. Vaccine-priming prior to leukapheresis to obtain antigen-specific peripheral blood T-cells for ex vivo expansion has been studied for the reconstitution of immunity to infectious agents [13, 14] . Investigators evaluated the ability to reconstitute protective immunity to S. pneumoniae by either collecting unprimed T-cells or by vaccinating Table 3 Changes in clonality/diversity of TCR Vβ repertoire following T-cell infusion The TCR Vβ repertoire clonality detections within CD4 and CD8 T-cell populations were performed using specific PCR amplifications in CDR3 region and Genescan assay on DNA analyzer Subtype of TCR Vβs in bold indicates new clonal population generated after T-cell infusion patients to obtain peripheral blood T-cells for ex vivo expansion and infusion [13] . T-cell products derived from patients who had been vaccinated prior to transplant, when administered in the first few weeks post-transplant, resulted in the generation of high levels of antigen-specific CD4 + T-cells which persisted for months after treatment. Moreover, antigens associated with robust precursor frequencies, such as CMV, were also observed to expand in vivo, potentially due to a bystander effect of the proliferative environment induced by lymphopenia and the infusion of large numbers of highly activated T-cells. The translation of these findings to the adoptive transfer of tumor antigen-specific T-cells derived from peripheral blood has not been as successful. In a study of metastatic melanoma, in patients who had been previously immunized with a gp100 vaccine, significant levels of gp100 specific T-cells could be generated by ex vivo culture and high levels of antigenspecific CD8
+ T-cells could be detected in the peripheral blood after transfer [15] . However, there were no demonstrable clinical responses. The investigators proposed several reasons for the lack of efficacy. Vaccine-induced T-cells may be highly restricted in antigen specificity thus have only a minor impact on the tumor. Moreover, studies of both the product and peripheral blood demonstrated that Treg were elevated, as many as 25 % of CD4 + T-cells expressed FOXP3 potentially limiting T-cell efficacy [16] . In contrast to melanoma, a highly immunogenic tumor, breast cancer induces low-level cellular immunity [17] . Regulatory cells may be actively attempting to limit the function of the significant numbers of tumor-specific T-cells already present in the peripheral blood and tumor of melanoma patients. Similar to the studies in infectious disease, we also observed the concurrent expansion of a number of HER2-specific T-cells directed against epitopes not used to stimulate the cell cultures. Studies by our group have demonstrated that HER2 vaccination elicits both inter-and intramolecular epitope spreading. Patients develop robust immunity to additional proteins expressed by breast cancer such as p53 and topoisomerase II alpha [4] . We did not have sufficient material to evaluate levels of immunity to antigens other than HER2, but presumably elevated levels of T-cells specific to additional antigens could be present in the T-cell products.
We did not observe the pulmonary toxicity observed with the use of HER2-specific CAR [10] . After infusion of 10 10 HER2-CAR, a patient developed respiratory distress with pulmonary infiltrate presumably due to the secretion of inflammatory cytokines by T-cells as well as crossreactivity to lung epithelial cells expressing lower levels of HER2 by the high avidity CAR. Vaccine-primed autologous T-cells are, most certainly, of a lower avidity than CAR in interaction with tumor cells or antigen presenting cells. However, the lower avidity of response, while limiting autoimmunity, may also enhance persistence and function of the T-cells in vivo. Recent studies have demonstrated that higher avidity T-cells are those most likely to be tolerized in the tumor environment and lose function [18, 19] . We did note inflammatory reactions associated with T-cell infusion in three patients. Investigators have reported 20 % of patients developed inflammation at sites of disease after transfer of EBV-specific T-cells [20] . The reactions we observed could indicate the potential for T-cell-induced toxicity, but also underscore the potential of the infused T-cells to traffic to the site of tumor and function.
In studies of adoptive T-cell therapy, efficacy of treatment has been associated with the magnitude of response achieved and the persistence of the T-cells in vivo [21, 22] . We observed in vivo augmentation of the Th1 response. In the T-cell product, approximately 1:5,000 cells (median) were T-cells specific for the stimulating HER2 antigens which significantly increased in vivo to a median of 1:1,500 PBMC. In patients with persistent immunity, the median number increased further to 1:600 PBMC specific for stimulating HER2 antigen. The development of multiple clonal populations over a short period of time, and temporally related to T-cell infusions, suggests antigen recognition. Skewing of the T-cell repertoire has been observed in active autoimmune disease such as thyroiditis [11] and has been identified in patients with cervical cancer where experiments demonstrated that the clonal Vβ species elicited recognized and lysed autologous tumor [23] . We do not know if the clonal populations we observed are HER2 specific or represent immunity to different antigens, but evidence suggests recognition of multiple epitopes and antigens is associated with tumor regression after adoptive transfer TIL in patients with metastatic melanoma [24] . We explored associations of response with immune biomarkers collected during the study. The number of Treg in the peripheral blood prior to T-cell infusion was a predictor of response. The negative prognostic impact of pre-infusion peripheral blood Treg cells has been documented for TILbased therapy by other investigators [25] . The magnitude of antigen-specific T-cells both in the product and in vivo and the diversity of the T-cell response were also associated with clinical outcome. These immunologic correlates provide a basis for exploration of biomarkers of response in future optimized protocols.
There is substantial evidence that type I T-cells play an important role in immune surveillance and even patients with advanced stage disease can derive clinical benefit from a robust endogenous type I T-cell response [26] . In only a minority of patients is type I immunity elicited by exposure to the tumor. Adoptive T-cell therapy, using vaccineprimed peripheral blood T-cells, may provide a therapeutic approach that would allow the delivery of type I antigenspecific T-cells to advanced stage patients with a variety of solid tumor types.
